Overview
- A Nature study published Wednesday analyzed nearly 28,000 23andMe users taking GLP-1 weight-loss drugs such as semaglutide or tirzepatide.
- One GLP1R variant (rs10305420) was tied to slightly greater weight loss, averaging about 1.7 extra pounds for one copy and just over 3 pounds for two.
- A GIPR variant (rs1800437) predicted higher nausea and vomiting on tirzepatide, with a rare two-gene combination linked to about a 15-fold higher vomiting risk.
- 23andMe released a GLP-1 “Weight Loss and Nausea” report inside its $499 Total Health service, which pairs results with clinician guidance.
- Experts called the genetic effects modest, noted partial replication in the NIH All of Us database, and said non-genetic factors like drug choice, dose, duration, age, and sex shape results more.